Ovarian cancer: Smart research approach identifies target proteins for potential anti-tumor drug

KREMS, Austria - Jan. 17, 2023 - PRLog -- Using an innovative research method, the identification of target proteins for the potential anti-tumor drug rhenium tricarbonyl (TRIP) in ovarian cancer cells was successfully achieved. Of the 89 proteins identified using chemoproteomics, the scaffold protein NUBP2 could be identified as a promising target for the recently discovered antitumor drug. These are the results of a scientific study by an international research team from the University of Vienna, Austria and Cornell University, USA around Benjamin Neuditschko, now a scientist at IMC Krems – University of Applied Sciences, which was recently published in the journal Angewandte Chemie International Edition. In it, they analyzed in more detail the cancer cell proteins TRIP interacts with and also the effects of different TRIP doses on the entire set of cancer cell proteins. The data thus obtained indicate that NUBP2 acts as a starting point for TRIP-induced cell death of cancer cells and that the potential drug is already effective at a very low dose.

Original publication: An Anticancer Rhenium Tricarbonyl Targets Fe−S Cluster Biogenesis in Ovarian Cancer Cells. Benjamin Neuditschko, A Paden King, Zhouyang Huang, Lukas Janker, Andrea Bileck, Yasmin Borutzki, Sierra C Marker, Christopher Gerner, Justin J Wilson, Samuel M Meier-Menches. Angewandte Chemie International Edition 2022 Oct 24;61(43):e202209136.https://doi.org/10.1002/anie.202209136

Copy Editing & Distribution

PR&D – Public Relations

for Research & Education

Dr. Barbara Bauder

Kollersteig 68

3400 Klosterneuburg / Austria

T +43 664 1576 350

E bauder@prd.at

W http://www.prd.at/ (https://doi.org/10.1002/anie.202209136)